CDKN2A and neoplasm: Of the 7 patients with paired biopsies of sufficient quality for analysis, just 2 showed qualitative modulation of tumor p16 staining in response to FdCyd-THU treatment: patient 1,010,019 exhibited a slight increase in p16 expression, while patient 1,010,020 exhibited a slight decrease (Table 4; Supplementary Fig. S6).